39 Yao Y, Tsirka SE. The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. *J Biol Chem* 2010; **285**: 31509–31516.
40 Sheehan JJ, Zhou C, Gravanis I, Rogove AD, Wu YP, Bogenhagen DF *et al.* Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice. *J Neurosci* 2007; **27**: 1738–1745.
41 Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) *via* a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. *J Biol Chem* 1999; **274**: 13066–13076.
42 Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. *J Clin Invest* 2005; **115**: 879–887.
43 Yokoo T, Kitamura M. Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. *Am J Physiol* 1996; **270**(1 Pt 2): F123–F130.
44 Levi M. Activated protein C in sepsis: a critical review. *Curr Opin Hematol* 2008; **15**: 481–486.
45 Gruber A, Marzec UM, Bush L, Di Cera E, Fernandez JA, Berny MA *et al.* Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. *Blood* 2007; **109**: 3733–3740.
46 Aoki Y, Ota M, Katsuura Y, Komoriya K, Nakagaki T. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats. *Arzneimittelforschung* 2000; **50**: 809–815.
47 Renckens R, Weijer S, de Vos AF, Pater JM, Meijers JC, Hack CE *et al.* Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. *Arterioscler Thromb Vasc Biol* 2004; **24**: 483–488.
48 Jourdain M, Carrette O, Tournoys A, Fourrier F, Mizon C, Mangalaboyi J *et al.* Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. *Am J Respir Crit Care Med* 1997; **156**: 1825–1833.
49 Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? *Crit Care Med* 2012; **40**: 2704–2708.
50 Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med* 2003; **348**: 138–150.
51 Hoetzenecker W, Echtenacher B, Guenova E, Hoetzenecker K, Woelbing F, Bruck J *et al.* ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. *Nat Med* 2012; **18**: 128–134.
52 Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N *et al.* Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. *Blood* 2009; **114**: 511–517.
53 Guo Y, Li J, Hagstrom E, Ny T. Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice. *PLoS One* 2011; **6**: e24774.
54 Walker MJ, McArthur JD, McKay F, Ranson M. Is plasminogen deployed as a Streptococcus pyogenes virulence factor? *Trends Microbiol* 2005; **13**: 308–313.
55 Berri F, Rimmelzwaan GF, Hanss M, Albina E, Foucault-Grunenwald ML, Le VB *et al.* Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. *PLoS Pathog* 2013; **9**: e1003229.

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

© 2015 Macmillan Publishers Limited

Biol Blood Marrow Transplant 20 (2014) 1150–1155

Comparable Long-Term Outcome of Unrelated Cord Blood Transplantation with Related Bone Marrow or Peripheral Blood Stem Cell Transplantation in Patients Aged 45 Years or Older with Hematologic Malignancies after Myeloablative Conditioning



Takaaki Konuma [1,*], Seiko Kato [1], Jun Ooi [2], Maki Oiwa-Monna [1], Toyotaka Kawamata [1], Arinobu Tojo [1], Satoshi Takahashi [1]

[1] *Department of Hematology/Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan*
[2] *Department of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan*

Article history:
Received 25 February 2014
Accepted 4 April 2014

Key Words:
Cord blood transplantation
Bone marrow transplantation
Peripheral blood stem cell transplantation
Related donor
Donor age

A B S T R A C T

We investigated whether bone marrow or peripheral blood stem cells from older sibling donors or cord blood from unrelated donors provided a better outcome in allogeneic hematopoietic stem cell transplantation for relatively older patients who were candidates for myeloablative conditioning. Clinical outcomes of 97 patients aged 45 years or older with hematologic malignancies who received unrelated cord blood transplantation (CBT) (n = 66) or bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) from related donors (n = 31) were compared. The cumulative incidences of grades III to IV acute and extensive chronic graft-versus-host diseases were similar between both groups. Although transplant-related mortality was significantly lower after CBT compared with BMT/PBSCT from related donors (hazard ratio [HR], .29, $P = .04$), overall mortality (HR, .72, $P = .47$) and relapse (HR, 2.02, $P = .23$) were not significantly different after CBT and BMT/PBSCT from related donors. These data suggest that CBT could be as safe and effective as BMT/PBSCT from older related donors for relatively older patients when it is used as a primary unrelated stem cell source.

© 2014 American Society for Blood and Marrow Transplantation.

INTRODUCTION

Donor age has been associated with transplant outcomes in allogeneic hematopoietic stem cell transplantation (allo-HSCT) after myeloablative conditioning or reduced-intensity conditioning (RIC) [1-5]. Older donor age resulted in an increased incidence of severe graft-versus-host disease (GVHD), which led to higher transplant-related mortality (TRM) or overall mortality after allo-HSCT from unrelated adult donors [1,2]. In contrast, it is difficult to determine the exact effect of the age of related donors, because increasing recipient age is frequently accompanied by increased donor age after allo-HSCT from related donors. However, older donor age of related donors may also be associated with adverse outcomes [3-5].

Several studies, including ours, comparing both cord blood transplantation (CBT) and bone marrow transplantation (BMT)/peripheral blood stem cell transplantation (PBSCT) from unrelated donors after myeloablative conditioning in adult patients demonstrated that the incidence of severe GVHD was significantly lower after CBT than after unrelated BMT/PBSCT. The survival rate and relapse incidence in CBT recipients were comparable with those in unrelated BMT/PBSCT recipients [6-9]. Moreover, we also demonstrated similar survival, relapse, and TRM between unrelated CBT and related BMT/PBSCT (rBMT/PBSCT) recipients [10]. The incidences of grades III to IV acute GVHD (aGVHD) and extensive chronic GVHD (cGVHD) among CBT recipients were also significantly lower than those among rBMT/PBSCT recipients. Because the lower risk of severe GVHD is one of the most attractive advantages of CBT, the use of cord blood instead of bone marrow or mobilized peripheral blood as a stem cell source might offer the possibility of decreasing severe GVHD in older patients. However, there has been no comparative study between CBT and BMT/PBSCT from older related donors after myeloablative conditioning in relatively older patients.

We previously reported that unrelated CBT after myeloablative conditioning is feasible in patients over the age of 45 years [11,12]. In this retrospective study, we report on a clinical comparison of CBT from unrelated donors and BMT/PBSCT from older related donors in patients older than 45 years of age with hematologic malignancies who were candidates for a myeloablative conditioning.

METHODS

Patients and Transplant Procedures

This retrospective study included 97 consecutive patients, 45 years of age or older, who received CBT (n = 66) from unrelated donors or BMT (n = 26) or PBSCT (n = 5) from related donors for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL) at the Institute of Medical Science, University of Tokyo between May 1992 and July 2013. Nineteen patients who received rBMT/PBSCT and 32 patients who received CBT were included from our previous study with extended

Financial disclosure: See Acknowledgments on page 1154.
* Correspondence and reprint requests: Takaaki Konuma, Department of Hematology/Oncology, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
E-mail address: tkonuma@ims.u-tokyo.ac.jp (T. Konuma).

1083-8791/$ – see front matter © 2014 American Society for Blood and Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2014.04.005

Table 1
Characteristics of Patients, Grafts, and Transplantation

Characteristic	rBMT/PBSCT	CBT	P
Number of patients	31	66	
Recipient age, yr, median (range)	48 (45-58)	49 (45-55)	.60
Recipient sex, n (%)			.51
Male	20 (64)	37 (56)	
Female	11 (35)	29 (43)	
Recipient CMV serostatus, n (%)			.18
Positive	28 (90)	64 (96)	
Negative	0 (0)	2 (3)	
Unknown	3 (9)	0 (0)	
Disease type, n (%)			.08
AML	16 (51)	44 (66)	
MDS	2 (6)	8 (12)	
CML	6 (19)	3 (4)	
ALL	3 (9)	8 (12)	
NHL	4 (12)	3 (4)	
Disease status at transplantation,* n (%)			.48
Standard	8 (25)	23 (34)	
High	23 (74)	43 (65)	
Conditioning regimen, n (%)			<.01
TBI12Gy+Ara-C/G-CSF	21 (64)	0 (0)	
TBI12Gy+Ara-C/G-CSF+CY	2 (6)	52 (78)	
TBI12Gy+Ara-C/G-CSF+Flu	0 (0)	3 (4)	
TBI12Gy+CY	3 (9)	3 (4)	
TBI12Gy+Ara-C+CY	1 (3)	8 (12)	
TBI12Gy+VP16	4 (12)	0 (0)	
GVHD prophylaxis, n (%)			.23
Cyclosporine A+methotrexate	29 (93)	65 (98)	
Cyclosporine A	2 (6)	1 (1)	
Number of nucleated cells, $\times10^7$/kg, median (range)	26.6 (3.13-50.0)‡	2.39 (1.72-5.07)	<.01
Number of CD34$^+$ cells, $\times10^5$/kg, median (range)	40.5 (20.6-75.0)§	1.04 (.17-3.15)	<.01
Donor age, yr, median (range)	46.5 (38-58)	—	—
Sex compatibility, n (%)			.81
Female donor to male recipient	8 (25)	20 (30)	
Other	23 (74)	46 (69)	
HLA disparities,† n (%)			<.01
0	28 (90)	1 (1)	
1	2 (6)	13 (19)	
2	1 (3)	52 (78)	
ABO incompatibility, n (%)			.04
Match	19 (61)	20 (30)	
Major mismatch	4 (12)	17 (25)	
Minor mismatch	5 (16)	18 (27)	
Bidirectional mismatch	3 (9)	11 (16)	
Time from diagnosis to transplantation, days, median (range)	521 (59-2501)	390.5 (55-6783)	.84
<365 d, n (%)	12 (38)	31 (46)	.51
≥365 d, n (%)	19 (61)	35 (53)	
Year of transplantation, n (%)			<.01
1992-2002	27 (87)	17 (25)	
2003-2013	4 (12)	49 (74)	
Follow-up for survivors, mo, median (range)	185 (32-258)	87 (4-175)	<.01

CMV indicates cytomegalovirus; CY, cyclophosphamide; Flu, fludarabine; VP-16, etoposide.
* Disease status at transplantation was classified as standard risk or high risk; CR1 or CR2 without poor prognostic karyotype for AML and ALL, refractory anemia for MDS, chronic phase for CML, and CR1 or CR2 for NHL were classified as standard risk, whereas patients in all other situations were classified as high risk.
† Number of HLA disparities defined as low resolution for HLA-A, -B, and -DR.
‡ Number of nucleated cells was only for BMT recipients.
§ Number of CD34$^+$ cells was only for PBSCT recipients.

follow-up [10]. For disease status at transplantation, patients in first complete remission (CR1) or second complete remission (CR2) without poor prognostic karyotype for AML and ALL, refractory anemia for MDS, chronic phase for CML, and CR1 or CR2 for NHL were classified as standard risk, whereas patients in all other situations were classified as high risk.

Although bone marrow or mobilized peripheral blood from HLA-compatible related donors within immediate families is a frontline graft source, patients without a suitable closely HLA-compatible related donor were eligible for CBT as an alternative first treatment option, unless they had any type of anti-HLA antibody. Cord blood units were obtained from the Japan Cord Blood Bank Network and were selected as reported previously [9,10]. All patients received 12 Gy total body irradiation (TBI)-based myeloablative conditioning regimens, and cyclosporine-based GVHD prophylaxis regimens, as previously reported [9,10]. For myeloid disease, granulocyte colony-stimulating factor (G-CSF) was added to the conditioning regimen to increase the susceptibility to cytosine arabinoside (Ara-C) through induction of cell cycle entry of dormant leukemia cells, as previously reported [10]. Almost all patients received some supportive care, such as antibacterial, antifungal and antiviral agents, as previously reported [9,10]. The institutional review board of the Institute of Medical Science, University of Tokyo approved this study, which was conducted in accordance with the Declaration of Helsinki.

End Points and Definitions

The primary study end point was overall survival (OS), which was defined as the time from the date of transplantation to the date of death or last contact. Secondary end points were relapse, TRM, GVHD, and neutrophil and platelet recovery. Relapse was defined by morphologic evidence of disease in peripheral blood, bone marrow, or extramedullary sites. TRM was defined as death during a remission. Both aGVHD and cGVHD were graded according to previously published criteria [13,14]. The incidence of aGVHD

was evaluated in all engrafted patients, whereas the incidence of cGVHD was evaluated in engrafted patients surviving more than 100 days. Neutrophil engraftment was defined as the first of 3 consecutive days during which the absolute neutrophil count was at least .5 × 10^9/L. Platelet engraftment was defined as the first of 7 consecutive days with a platelet count of 20 × 10^9/L or higher without platelet transfusion.

Statistical Analysis

Baseline patient and transplant characteristics were compared using the chi-square test for categorical variables and the Mann-Whitney U test for continuous variables. The probability of OS was estimated according to the Kaplan-Meier method, and groups were compared using Cox regression models or the log-rank test. The probabilities of relapse, TRM, aGVHD and cGVHD, and neutrophil and platelet engraftment were estimated based on a cumulative incidence method to accommodate competing risks. Multivariate analysis was performed with a Cox proportional hazard model adjusted for OS and a Fine and Gray proportional hazards model for the others. In addition to the stem cell source (CBT versus rBMT/PBSCT), the following variables were considered: disease type (myeloid [AML, MDS, CML] versus lymphoid [ALL, NHL] disease), disease status at transplantation (standard risk versus high risk), time from diagnosis to transplantation (<365 days versus ≥365 days), sex compatibility between donor and recipient (female donor to male recipient versus other), ABO compatibility between donor and recipient (match versus mismatch), and year of transplantation (1992 to 2002 versus 2003 to 2013).

All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphic user interface for R 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria) [15]. $P < .05$ was considered significant. Analysis of data was performed in December 2013.

RESULTS

Characteristics of Patients and Grafts

The characteristics of patients, grafts, and transplant procedures are summarized in Table 1. Recipients' age, sex, cytomegalovirus serostatus, disease type, disease status at transplantation, GVHD prophylaxis, sex incompatibility between donors and recipients, and time from diagnosis to transplantation were almost the same between the CBT and rBMT/PBSCT recipients. On the other hand, there were significant differences in the following variables (Table 1). The conditioning regimen significantly differed between the CBT and rBMT/PBSCT recipients ($P < .01$). The most common conditioning regimen was TBI12Gy+Ara-C/G-CSF+cyclophosphamide (78%) for CBT and TBI12Gy+Ara-C/G-CSF (64%) for rBMT/PBSCT. The number of nucleated cells or CD34$^+$ cells for CBT recipients was 1 log lower than in rBMT or rPBSCT recipients, respectively. The proportion of HLA disparity and ABO incompatibility was higher among CBT recipients than rBMT/PBSCT recipients. CBT was more frequently performed in recent years, resulting in the significantly shorter follow-up period for CBT compared with that for rBMT/PBSCT. Median follow-up was 185 months (range, 32 to 258 months) for rBMT/PBSCT recipients and 87 months (range, 4 to 175 months) for CBT recipients ($P < .01$).

Table 2
Univariate and Multivariate Analysis of Transplant Outcomes after rBMT/PBSCT and CBT in Patients Aged 45 Years or Older

	Univariate Analysis		Multivariate Analysis*	
	HR (95% CI)	P	HR (95% CI)	P
Neutrophil engraftment				
rBMT/PBSCT vs. CBT	.69 (.38-1.04)	.07	.46 (.26-.81)	<.01
Platelet engraftment				
rBMT/PBSCT vs. CBT	.30 (.14-.61)	<.01	.24 (.12-.50)	<.01
Grades III-IV aGVHD				
rBMT/PBSCT vs. CBT	.57 (.18-1.85)	.36	.53 (.15-1.90)	.34
Extensive cGVHD				
rBMT/PBSCT vs. CBT	1.01 (.53-1.91)	.97	1.08 (.49-2.35)	.84
Overall mortality				
rBMT/PBSCT vs. CBT	.69 (.36-1.32)	.26	.72 (.30-1.73)	.47
Relapse				
rBMT/PBSCT vs. CBT	1.42 (.52-3.87)	.49	2.02 (.63-6.42)	.23
TRM				
rBMT/PBSCT vs. CBT	.38 (.16-.93)	.03	.29 (.08-.99)	.04

* For neutrophil engraftment, lymphoid disease was also a significant variable (HR, 2.40; 95% CI, 1.52 to 3.79; $P < .01$). For platelet engraftment, lymphoid disease was also a significant variable (HR, 1.74; 95% CI, 1.17 to 2.59; $P < .01$). For grades III-IV aGVHD, ABO incompatibility was a significant variable (HR, 4.41; 95% CI, 1.06 to 18.24; $P = .04$). For extensive cGVHD, high risk of disease status at transplantation was a significant variable (HR, 3.14; 95% CI, 1.39 to 7.09; $P < .01$). For overall mortality, high risk of disease status at transplantation (HR, 3.33; 95% CI, 1.36 to 8.11; $P < .01$) and ABO incompatibility (HR, 3.14; 95% CI, 1.44 to 6.87; $P < .01$) were significant variables. For relapse, high risk of disease status at transplantation was a significant variable (HR, 4.55; 95% CI, 1.08 to 19.23; $P = .03$). For TRM, female donor to male recipient (HR, 2.89; 95% CI, 1.11 to 7.52; $P = .02$) and ABO incompatibility (HR, 5.20; 95% CI, 1.56 to 17.33; $P < .01$) were also significant variables.

Neutrophil and Platelet Engraftment

One patient in the CBT group died on day 21 due to encephalitis, and 1 patient in the rBMT/PBSCT group died on day 7 due to organ failure. Primary graft failure occurred in 3 of the surviving 65 patients in the CBT group, but there was no primary graft failure in the rBMT/PBSCT group. As expected, neutrophil recovery was significantly delayed after CBT as compared with rBMT/PBSCT. Median times to neutrophil recovery were 22 days (range, 18 to 34 days) after CBT, as compared with 18 days (range, 11 to 40 days) after rBMT/PBSCT ($P < .01$). The cumulative incidence of neutrophil recovery on day 60 was slightly lower after CBT (93.9%; 95% confidence interval [CI], 83.5% to 97.9%) compared with rBMT/PBSCT (96.8%; 95% CI, 57.8% to 99.8%) ($P = .07$). In the multivariate analysis, the hazard risk of neutrophil engraftment was significantly lower after CBT as compared with rBMT/PBSCT (hazard ratio [HR], .46; 95% CI, .26 to .81; $P < .01$, Table 2).

Platelet recovery was also significantly delayed after CBT as compared with rBMT/PBSCT. Median times to platelet recovery were 42 days (range, 13 to 104 days) after CBT, as compared with 24 days (range, 15 to 300 days) after rBMT/PBSCT ($P < .01$). The cumulative incidence of platelet recovery on day 100 was significantly lower after CBT (90.8%; 95% CI, 80.0% to 95.9%) compared with rBMT/PBSCT (93.5%; 95% CI, 71.5% to 98.7%) in the univariate analysis ($P < .01$); the difference was also significant in multivariate analyses (HR, .24; 95% CI, .12 to .50; $P < .01$, Table 2).

Acute and Chronic GVHD

The cumulative incidences of grades II to IV (HR, .90; 95% CI, .49 to 1.64; $P = .76$) and grades III to IV aGVHD (HR, .53; 95% CI, .15 to 1.90; $P = .34$) were similar between CBT and rBMT/PBSCT recipients in multivariate analyses (Table 2). The unadjusted cumulative incidence of grades III to IV aGVHD at 100 days was 9.2% (95% CI, 3.7% to 17.8%) in CBT recipients and 16.1% (95% CI, 5.7% to 31.2%) in rBMT/PBSCT recipients ($P = .35$). Extensive cGVHD developed in 27 of 58 CBT recipients and in 13 of 27 rBMT/PBSCT recipients surviving more than 100 days. In a multivariate analysis, the cumulative incidences of cGVHD (HR, .94; 95% CI, .55 to 1.62; $P = .84$) and extensive cGVHD (HR, 1.08; 95% CI, .49 to 2.35; $P = .84$) were similar between CBT and rBMT/PBSCT recipients in multivariate analysis (Table 2).



Figure 1. Outcomes after CBT or BMT/PBSCT from related donors in patients aged 45 years or older with hematologic malignancies after a myeloablative conditioning regimen. Adjusted probability of OS (A), unadjusted cumulative incidence of relapse (B), and TRM (C).

Table 3
Cause of Death

	Death before 100 Days		Death after 100 Days	
	rBMT/PBSCT (n = 2)	CBT (n = 4)	rBMT/PBSCT (n = 14)	CBT (n = 19)
Primary disease	0	2	5	12
GVHD	0	0	5	5
Infection	1	2	4	2
Organ failure	1	0	0	0

Survival, Relapse, and TRM

The adjusted probabilities of OS at 5 years were 67.4% (95% CI, 55.7% to 81.6%) for recipients of CBT and 55.2% (95% CI, 39.4% to 77.4%) for recipients of rBMT/PBSCT (Figure 1A). In multivariate analysis, the hazard risk of overall mortality was similar between CBT and rBMT/PBSCT recipients (HR, .72; 95% CI, .30 to 1.73; $P = .47$; Table 2). We also compared OS of both groups for each disease risk. However, OS of both recipient groups was also equivalent in standard-risk patients (n = 31) and high-risk patients (n = 66) (data not shown). The unadjusted cumulative incidence of relapse at 5 years was 22.0% (95% CI, 12.7% to 33.0%) in CBT recipients and 16.7% (95% CI, 5.9% to 32.3%) in rBMT/PBSCT recipients ($P = .48$) (Figure 1B). In multivariate analysis, the hazard risk for relapse was similar between CBT and rBMT/PBSCT recipients (HR, 2.02; 95% CI, .63 to 6.42; $P = .23$; Table 2). The unadjusted cumulative incidence of TRM was significantly lower after CBT at 100 days (3.0%; 95% CI, .6% to 9.4%) and 5 years (15.8%; 95% CI, 7.6% to 26.6%) compared with rBMT/PBSCT at 100 days (6.5%; 95% CI, 1.1% to 18.9%) and 5 years (32.7%; 95% CI, 16.8% to 49.6%) ($P = .04$) (Figure 1C). In multivariate analysis, the hazard risk of TRM was significantly lower after CBT as compared with rBMT/PBSCT (HR, .29; 95% CI, .08 to .99; $P = .04$; Table 2).

We also analyzed a subgroup of patients aged 50 years or older after CBT (n = 29) and rBMT/PBSCT (n = 11). In multivariate analysis, the hazard risk of overall mortality (HR, .36, $P = .10$) and relapse (HR, 2.73, $P = .41$) after CBT was comparable with that after rBMT/PBSCT, respectively. However, the hazard risk of TRM was lower after CBT than after rBMT/PBSCT (HR, .16; 95% CI, .04 to .56; $P < .01$).

The causes of death before and after 100 days after transplantation by donor type are summarized in Table 3. The major cause of death in both recipient groups was primary disease. However, GVHD and infection as a primary cause of late mortality were more common after rBMT/PBSCT compared with CBT.

DISCUSSION

The objective of this study was to compare the transplant outcomes after CBT and rBMT/PBSCT in relatively older patients who were candidates for myeloablative conditioning. Unexpectedly, there were no significant differences in aGVHD and cGVHD between CBT and rBMT/PBSCT recipients. However, TRM was higher after rBMT/PBSCT compared with CBT. The reduced TRM in CBT might be in part due to improved supportive care, because CBT was more frequently performed in recent years. However, year of transplantation did not affect any clinical results in our multivariate analysis. On the other hand, we used almost the same 12-Gy TBI-based myeloablative conditioning and cyclosporine-based GVHD prophylaxis regimens during the period for both recipients of CBT and rBMT/PBSCT. Among relatively older

patients who were candidates for such myeloablative conditioning, survival and relapse were not significantly different after CBT and rBMT/PBSCT.

Whether an older sibling donor or unrelated donor should be chosen as an optimal donor is an important question in allo-HSCT for older patients. There have been some clinical comparisons of allo-HSCT from older sibling donors and unrelated donors in older patients [16-18]. A European Group for Blood and Marrow Transplantation analysis by Kröger et al. [16] reported on comparisons of allo-HSCT from older sibling donors and young unrelated donors in 719 patients older than 50 years with MDS. They showed that recipients from young unrelated donors had improved survival compared with those from older sibling donors among older patients with MDS. A single-institute analysis by Ayuk et al. [17] showed similar outcomes from older sibling donors compared with young unrelated donors among older patients with AML in CR. On the other hand, Alousi et al. [18] of the Center for International Blood and Marrow Transplantation also performed a similar study in 2172 patients older than 50 years with leukemia or lymphoma. In contrast, their data showed that the risks of overall mortality, relapse, and TRM were lower after allo-HSCT from older sibling donors compared with those from young unrelated donors. However, comparative clinical outcomes of CBT and BMT/PBSCT from older related donors after myeloablative conditioning have yet to be clarified. Our data showed comparable outcomes for CBT and BMT/PBSCT from older related donors after myeloablative conditioning in relatively older patients when cord blood was selected as a primary unrelated donor source.

In comparison with other sources of allo-HSCT, the lower risk of GVHD without compromised graft-versus-leukemia effects is one of the most important advantages of CBT. In our study, the incidences of severe aGVHD and cGVHD were not significantly different after CBT and rBMT/PBSCT. Relapse was also similar between CBT and rBMT/PBSCT recipients. However, TRM was significantly lower after CBT compared with that after rBMT/PBSCT. GVHD-associated mortality was a common cause of late death after rBMT/PBSCT compared with CBT. Newell et al. [19] reported a shorter duration and a higher response of cGVHD to systemic immunosuppressive treatment in CBT recipients than in BMT/PBSCT recipients, suggesting that a longer duration of systemic immunosuppressive treatment for cGVHD might have contributed to higher infection-related late mortality after rBMT/PBSCT compared with CBT. In fact, we previously reported that the termination of immunosuppressive treatment for rBMT/PBSCT recipients was slower than those for CBT recipients [10]. These effects might have contributed to higher TRM after rBMT/PBSCT compared with CBT in our study. In addition, the absence of risk for donors may also be one of the most attractive advantages of CBT for older patients. Older patients generally have older donors as well when they have an HLA-compatible sibling. Because older donors are more likely to have organ dysfunction or comorbidity, older patients hardly ever find healthy sibling donors. These problems could be overcome with the advantages of CBT, especially in older patients.

Myeloablative conditioning regimens for allo-HSCT have been restricted to younger patients and those without comorbidities, because TRM occurs more frequently among older patients and those with serious comorbidities. RIC regimens have recently been expanded for use with graft sources not only from bone marrow or mobilized peripheral blood but also from cord blood. Although the risk of graft failure after CBT has been reported to be higher after RIC compared with myeloablative conditioning [20], several reports showed similar survival with acceptable engraftment between CBT and other graft sources from related and unrelated adult donors after RIC [21,22]. Further studies are warranted to establish optimal RIC regimens for CBT.

In conclusion, our data showed that CBT had almost equivalent results compared with rBMT/PBSCT after myeloablative conditioning for relatively older patients. However, these results should be interpreted with caution because this study was a retrospective single-institute analysis that included a heterogeneous population and a relatively small number of patients. In addition, although our study was performed in patients older than 45 years of age, it should be noted that most patients were younger than 55 years of age. This is because the patients in our cohort received myeloablative conditioning, which often excludes even older patients. As such, our results cannot be extended to patients older than 60 years of age until another similar study is performed using RIC in those older than 55 years. Although these findings should be confirmed in larger prospective studies, CBT could be as safe and effective as BMT/PBSCT from older related donors after myeloablative conditioning for relatively older patients when it is used as a primary unrelated stem cell source.

ACKNOWLEDGMENTS

The authors thank all the physicians and staff at the hospitals and the 8 cord blood banks in Japan for their help in this study.

Financial disclosure: Supported in part by The Kobayashi Foundation.

Conflict of interest statement: There are no conflicts of interest to report.

REFERENCES

1. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. *Blood*. 2001;98:2043-2051.
2. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. *Blood*. 2012;119:296-307.
3. Mehta J, Gordon LI, Tallman MS, et al. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? *Bone Marrow Transplant*. 2006;38:95-100.
4. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. *J Clin Oncol*. 2006;24:5695-5702.
5. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. *Blood*. 2011;117:3214-3219.
6. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. *N Engl J Med*. 2004;351:2265-2275.
7. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. *N Engl J Med*. 2004;351:2276-2285.
8. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. *Lancet Oncol*. 2010;11:653-660.
9. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. *Blood*. 2004;104:3813-3820.
10. Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related

donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. *Blood*. 2007;109:1322-1330.
11. Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation after myeloablative conditioning in patients over the age of 45 years. *Br J Haematol*. 2004;126:711-714.
12. Konuma T, Ooi J, Takahashi S, et al. Unrelated cord blood transplantation after myeloablative conditioning in patients with acute leukemia aged between 50 and 55 years. *Bone Marrow Transplant*. 2006;37:803-804.
13. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow Transplant*. 1995;15:825-828.
14. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. *Am J Med*. 1980;69:204-217.
15. Kanda Y. Investigation of the freely-available easy-to-use software "EZR" (Easy R) for medical statistics. *Bone Marrow Transplant*. 2013;48:452-458.
16. Kröger N, Zabelina T, de Wreede L, et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. *Leukemia*. 2013;27:604-609.
17. Ayuk F, Zabelina T, Wortmann F, et al. Donor choice according to age for allo-SCT for AML in complete remission. *Bone Marrow Transplant*. 2013;48:1028-1032.
18. Alousi AM, Le-Rademacher J, Saliba RM, et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? *Blood*. 2013;121:2567-2573.
19. Newell LF, Flowers ME, Gooley TA, et al. Characteristics of chronic GVHD after cord blood transplantation. *Bone Marrow Transplant*. 2013;48:1285-1290.
20. Cutler C, Ballen K. Reduced-intensity conditioning and umbilical cord blood transplantation in adults. *Bone Marrow Transplant*. 2009;44:667-671.
21. Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. *Biol Blood Marrow Transplant*. 2008;14:282-289.
22. Peffault de Latour R, Brunstein CG, Porcher R, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. *Biol Blood Marrow Transplant*. 2013;19:1355-1360.

Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan

Cord blood transplantation (CBT) from an unrelated donor has been increasingly used as an alternative transplant method for adult patients without human leukocyte antigen (HLA)-compatible related or unrelated donors.[1-4] However, the main disadvantage of CBT is still the limited cell dose, especially in adults, and this might contribute to a higher incidence of graft failure and delayed hematopoietic recovery, leading to higher transplant-related mortality (TRM) or overall mortality after CBT.

The purpose of a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematologic malignancies is disease eradication and immunosuppression to overcome graft rejection. Although the standard myeloablative conditioning regimen prior to allo-HSCT has been total body irradiation (TBI) or busulfan combined with cyclophosphamide (CY) for patients with adult acute myeloid leukemia (AML), the role of an intensified conditioning regimen has been analyzed extensively in order to reduce the rate of post-transplant relapse and improve survival.[5-7] However, the majority of these studies analyzed patients receiving allo-HSCT using bone marrow (BM) or mobilized peripheral blood (PB) as a stem cell source. Therefore, an optimal myeloablative conditioning regimen prior to CBT for adult AML still has to be determined.

Granulocyte colony-stimulating factor (G-CSF) stimulates proliferation, differentiation, and functional activation of neutrophils. In clinical use, G-CSF is most commonly used for reducing the duration of neutropenia after chemotherapy and HSCT, and for the mobilization of hematopoietic stem/progenitor cells from the BM into PB

Table 1. Characteristics of patients, cord blood units, and transplantation.

	Total	TBI≥10Gy+Ara-C +CY	TBI≥10Gy+Ara-C /G-CSF+CY	TBI≥10Gy+other	TBI<10Gy+other or non-TBI	P
Number of patients	438	163	80	156	39	
Age						0.61
16-39 years	226(52 %)	74(45 %)	40(50 %)	81(52 %)	17(44 %)	
40-55 years	212(48 %)	89(54 %)	40(50 %)	75(48 %)	22(56 %)	
Sex						0.82
Male	217(50 %)	83(50 %)	42(53 %)	73(47 %)	19(49 %)	
Female	221(50 %)	80(49 %)	38(48 %)	83(56 %)	20(51 %)	
Disease status at CBT *						0.32
Standard risk	214 (49 %)	74(45 %)	45(56 %)	79(51 %)	16(41 %)	
High risk	221(50 %)	87(53 %)	35(44 %)	76(49 %)	23(59 %)	
Unknown	3(<1 %)	2(1 %)	0	1(<1 %)	0	
GVHD prophylaxis						<0.001
Cyclosporine A+methotrexate	304(69 %)	107(66 %)	74(93 %)	100(64 %)	23(59 %)	
Tacrolimus+methotrexate	134(31 %)	56(34 %)	6(8 %)	56(39 %)	16(41 %)	
Number of nucleated cells						0.71
$<2.5\times10^7$/kg	204(47 %)	70(43 %)	40(50 %)	75(48 %)	19(49 %)	
$\geq2.5\times10^7$/kg	200(46 %)	79(48 %)	33(41 %)	70(45 %)	18(37 %)	
Unknown	34(8 %)	14(9 %)	7(9 %)	11(7 %)	2(5 %)	
Number of CD34$^+$cells						0.23
$<1\times10^5$/kg	279(64 %)	110(67 %)	43(54 %)	101(64 %)	25(64 %)	
$\geq1\times10^5$/kg	144(33 %)	52(32 %)	34(43 %)	46(29 %)	12(31 %)	
Unknown	15(3 %)	1(<1 %)	3(4 %)	9(6 %)	2(5 %)	
HLA disparities†						0.24
0	40(9 %)	9(6 %)	7(9 %)	19(1 %)	5(1 %)	
1	148(34 %)	64(39 %)	22(28 %)	50(1 %)	12(1 %)	
≥2	250(57 %)	90(55 %)	51(64 %)	87(1 %)	22(1 %)	
ABO incompatibility						0.11
Match	152(35 %)	67(41 %)	29(36 %)	42(27 %)	14(39 %)	
Major/bidirectional mismatch	175(25 %)	30(18 %)	22(28 %)	47(30 %)	11(28 %)	
Minor mismatch	110(40 %)	66(40 %)	29(36 %)	66(42 %)	14(39 %)	
Unknown	1(<1 %)	0	0	1(<1 %)	0	
Year of CBT						<0.001
1998-2002	56(13 %)	12(7 %)	16(20 %)	24(15 %)	4(10 %)	
2003-2005	158(36 %)	40(25 %)	32(40 %)	64(41 %)	22(56 %)	
2006-2008	224(51 %)	111(68 %)	32(40 %)	68(44 %)	13(33 %)	

**Disease status at CBT was classified as standard risk or high risk; complete remission without poor prognostic karyotype according to the MRC10 criteria was classified as standard risk, whereas patients in all other situations were classified as high risk. †The number of HLA disparities was defined as low resolution for HLA-A, -B, and –DR in graft-versus-host direction. Ara-C: cytosine arabinoside; CBT: cord blood transplantation; CY: cyclophosphamide; G-CSF: granulocyte colony-stimulating factor; GvHD: graft-versus-host disease; HLA: human leukocyte antigen; TBI: total body irradiation.*

for HSCT. Furthermore, since administration of G-CSF increases the susceptibility to cytarabine arabinoside (Ara-C) through induction of cell cycle entry of dormant leukemia cells,[8,9] the efficacy of concomitant use of G-CSF and chemotherapy has been analyzed.[10,11] Several studies, as well as our own single institute studies, have demonstrated that G-CSF combined with myeloablative conditioning prior to allo-HSCT could be safely and effectively used for patients with myeloid malignancies in a single arm trial.[9,12,13] However, there has been no comparative study of transplant outcomes for AML after allo-HSCT following a conditioning regimen with or without G-CSF. This retrospective study is the first to assess the effect of a G-CSF combination in a myeloablative conditioning regimen for CBT on the transplant outcome in adult AML patients in Japan. Patients and study methods are described in the *Online Supplementary Appendix*.

Characteristics of patients and cord blood units are shown in Table 1. There was a significant difference in cumulative incidence of neutrophil recovery among the four groups in univariate analysis (P<0.001) (Figure 1A). In the multivariate analysis, the hazard risk of neutrophil engraftment was significantly higher in the TBI≥10Gy+Ara-C/G-CSF+CY group (P<0.001) and lower in the TBI≥10Gy+other group (P=0.03) and TBI<10Gy+other or non-TBI group (P<0.001) compared with the TBI≥10Gy+Ara-C+CY group (Table 2). Among patients achieving neutrophil engraftment, neutrophil recovery times were significantly shorter in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P<0.001). There was a significant difference in cumulative incidence of platelet recovery among the four groups in univariate analysis (P<0.001) (Figure 1B). Multivariate analysis showed no significant difference between the TBI≥10Gy+Ara-C+CY group and TBI≥10Gy+Ara-C/G-CSF+CY group (P=0.14). However, the hazard risk of platelet engraftment was significantly lower in the TBI≥10Gy+other group (P<0.001) and TBI<10Gy+other or non-TBI group (P<0.001) compared with the TBI≥10Gy+Ara-C+CY group (Table 2). Among patients achieving platelet engraftment, there was no significant difference in platelet recovery times among the four groups (P=0.32).

Among patients in the entire cohort, the cumulative incidence of TRM at 100 days and at one year was 17% (95%CI: 13%-20%) and 22% (95%CI: 18%-26%), respectively. There was no significant difference in cumulative incidence of TRM at one year among the four groups in univariate analysis (P=0.19) (Figure 1C). Multivariate analysis of TRM, adjusting for other variables, showed no significant difference between the TBI≥10Gy+Ara-C+CY group and the TBI≥10Gy+Ara-C/G-CSF+CY group (P=0.67), TBI≥10Gy+other group (P=0.25), or TBI<10Gy+other or non-TBI group (P=0.95) (Table 2). The cumulative incidence of relapse at three years was 30% (95%CI: 25%-35%) in the entire cohort. There was no significant difference in cumulative incidence of relapse at three years among the four groups (P=0.05) (Figure 1D). In multivariate analysis, the hazard risk of relapse was lower in the TBI≥10Gy+Ara-C/G-CSF+CY group (P=0.03), but not in the TBI≥10Gy+other group (P=0.94) and TBI<10Gy+other or non-TBI group (P=0.73) compared with the TBI≥10Gy+Ara-C+CY group (Table 2).

Among the entire cohort, the probability of disease-free survival (DFS) and overall survival (OS) at three years was 44% (95%CI: 39%-49%) and 52% (95%CI: 46%-57%), respectively. There was a significant difference in the probability of DFS at three years among the four groups in univariate analysis (P=0.001) (Figure 1E). The probability of

Table 2. Multivariate analysis of transplant outcomes.

Outcomes	N. of patients	HR (95 % CI)	*P*
Neutrophil engraftment			
Conditioning regimen			
TBI≥10Gy+Ara-C+CY	163	1	Reference
TBI≥10Gy+Ara-C/G-CSF+CY	80	1.57(1.17-2.11)	0.002
TBI≥10Gy+other	156	0.76(0.58-0.98)	0.03
TBI<10Gy+other or non-TBI	39	0.46(0.27-0.78)	0.004
Number of CD34$^+$cells			
<1×10^5/kg	279	1	Reference
≥1×10^5/kg	144	1.56(1.23-1.98)	<0.001
Platelet engraftment			
Conditioning regimen			
TBI≥10Gy+Ara-C+CY	163	1	Reference
TBI≥10Gy+Ara-C/G-CSF+CY	80	1.25(0.92-1.71)	0.14
TBI≥10Gy+other	156	0.54(0.39-0.73)	<0.001
TBI<10Gy+other or non-TBI	39	0.40(0.23-0.67)	<0.001
Number of CD34$^+$cells			
<1×10^5/kg	279	1	Reference
≥1×10^5/kg	144	1.58(1.22-2.06)	<0.001
Transplant-related mortality			
Conditioning regimen			
TBI≥10Gy+Ara-C+CY	163	1	Reference
TBI≥10Gy+Ara-C/G-CSF+CY	80	0.86(0.44-1.68)	0.67
TBI≥10Gy+other	156	1.31(0.82-2.10)	0.25
TBI<10Gy+other or non-TBI	39	1.02(0.46-2.25)	0.95
Age			
<40 years	226	1	Reference
≥40 years	212	1.64(1.08-2.49)	0.01
Disease status at CBT			
Standard risk	214	1	Reference
High risk	221	1.81(1.20-2.72)	0.004
Relapse			
Conditioning regimen			
TBI≥10Gy+Ara-C+CY	163	1	Reference
TBI≥10Gy+Ara-C/G-CSF+CY	80	0.45(0.21-0.95)	0.03
TBI≥10Gy+other	156	0.98(0.61-1.57)	0.94
TBI<10Gy+other or non-TBI	39	1.14(0.53-2.44)	0.73
Disease status at CBT			
Standard risk	214	1	Reference
High risk	221	3.28(2.16-4.98)	<0.001
Treatment failure			
Conditioning regimen			
TBI≥10Gy+Ara-C+CY	163	1	Reference
TBI≥10Gy+Ara-C/G-CSF+CY	80	0.57(0.36-0.91)	0.01
TBI≥10Gy+other	156	1.24(0.90-1.70)	0.17
TBI<10Gy+other or non-TBI	39	1.24(0.75-2.02)	0.39
Disease status at CBT			
Standard risk	214	1	Reference
High risk	221	3.10(2.29-4.19)	<0.001
Overall mortality			
Conditioning regimen			
TBI≥10Gy+Ara-C+CY	163	1	Reference
TBI≥10Gy+Ara-C/G-CSF+CY	80	0.52(0.31-0.87)	0.01
TBI≥10Gy+other	156	1.19(0.84-1.69)	0.31
TBI<10Gy+other or non-TBI	39	1.25(0.74-2.12)	0.39
Disease status at CBT			
Standard risk	214	1	Reference
High risk	221	2.68(1.93-3.71)	<0.001

The only significant variables other than conditioning regimen were described in each end point. Variables considered in multivariate analysis were conditioning regimen (TBI≥10Gy+Ara-C+CY vs. TBI≥10Gy+Ara-C/G-CSF+CY vs. TBI≥10Gy+other vs. TBI<10Gy+other or non-TBI), age (<40 vs. ≥40 years), patients' gender (male vs. female), disease status at CBT (standard risk vs. high risk), GVHD prophylaxis (cyclosporine A with methotrexate vs. tacrolimus with methotrexate), cord blood nucleated cell count (<2.5x10^7/kg vs. ≥2.5x10^7/kg), cord blood CD34$^+$ cell count (<1x10^5/kg vs. ≥1x10^5/kg), HLA disparities (0 vs. 1 vs. ≥2), donor–recipient ABO compatibility (match vs. major/bidirectional mismatch vs. minor mismatch), and year of CBT (1998-2002 vs. 2003-2005 vs. 2006-2008). Ara-C: cytosine arabinoside; CBT: cord blood transplantation; CI: confidence interval; CY: cyclophosphamide; G-CSF: granulocyte colony-stimulating factor; HR: hazard ratio; TBI: total body irradiation.



Figure 1. Cumulative incidences of neutrophil (A) and platelet (B) recovery, transplant-related mortality (TRM) (C) and relapse (D), probabilities of disease-free survival (E) and overall survival (F) after cord blood transplantation according to conditioning regimen. (A) Cumulative incidence of neutrophil recovery 42 days after CBT was 88% [95% confidence interval (CI): 81%-92%] in the TBI≥10Gy+Ara-C+CY group, 95% (95%CI: 85%-98%) in the TBI≥10Gy+Ara-C/G-CSF+CY group, 74% (95%CI: 66%-81%) in the TBI≥10Gy+other group, and 57% (95%CI: 37%-70%) in the TBI<10Gy+other or non-TBI group. Median times to neutrophil recovery were 24 days (range 17-53 days) in the TBI≥10Gy+Ara-C+CY group, 22 days (range 16-34 days) in the TBI≥10Gy+Ara-C/G-CSF+CY group, 23 days (range 15-65 days) in the TBI≥10Gy+other group, and 22 days (range 15-42 days) in the TBI<10Gy+other or non-TBI group. (B) Cumulative incidence of platelet recovery 100 days after CBT was 82% (95%CI: 74%-87%) in the TBI≥10Gy+Ara-C+CY group, 85% (95%CI: 74%-92%) in the TBI≥10Gy+Ara-C/G-CSF+CY group, 58% (95%CI: 48%-66%) in the TBI≥10Gy+other group, and 47% (95%CI: 25%-62%) in the TBI<10Gy+other or non-TBI group. Median times to platelet recovery were 46 days (range 28-168 days) in the TBI≥10Gy+Ara-C+CY group, 45.5 days (range 27-263 days) in the TBI≥10Gy+Ara-C/G-CSF+CY group, 48 days (range 20-249 days) in the TBI≥10Gy+other group, and 51 days (range 22-109 days) in the TBI<10Gy+other or non-TBI group. (C) Cumulative incidence of TRM at one year was 21% (95%CI: 15%-27%) in the TBI≥10Gy+Ara-C+CY group, 15% (95%CI: 8%-23%) in the TBI≥10Gy+Ara-C/G-CSF+CY group, 27% (95%CI: 20%-35%) in the TBI≥10Gy+other group, and 27% (95%CI: 14%-42%) in the TBI<10Gy+other or non-TBI group. (D) Cumulative incidence of relapse at three years was 37% (95%CI: 28%-46%) in the TBI≥10Gy+Ara-C+CY group, 18% (95%CI: 10%-27%) in the TBI≥10Gy+Ara-C/G-CSF+CY group, 30% (95%CI: 22%-37%) in the TBI≥10Gy+other group, and 36% (95%CI: 20%-52%) in the TBI<10Gy+other or non-TBI group. (E) Probability of disease-free survival at three years was 40% (95%CI: 31%-49%) for the TBI≥10Gy+Ara-C+CY group, 64% (95%CI: 52-74%) for the TBI≥10Gy+Ara-C/G-CSF+CY group, 38% (95%CI: 30%-47%) for the TBI≥10Gy+other group, and 36% (95%CI: 20%-51%) for the TBI<10Gy+other or non-TBI group. (F) Probability of overall survival was 52% (95%CI: 42%-60%) for the TBI≥10Gy+Ara-C+CY group, 70% (95%CI: 57%-79%) for the TBI≥10Gy+Ara-C/G-CSF+CY group, 45% (95%CI: 36%-54%) for the TBI≥10Gy+other group, and 39% (95%CI: 22%-55%) for the TBI<10Gy+other or non-TBI group. Median period of follow up for survivors (n=261) in the entire cohort was 24 months (range 1-122 months) after CBT.

DFS at three years was significantly better in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P=0.02), the TBI≥10Gy+other group (P=0.002) and TBI<10Gy+other or non-TBI group (P=0.006). Multivariate analysis showed significantly decreased rates of treatment failure in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P=0.01) (Table 2). In univariate analysis, there was a significant difference in the probability of OS at three years among the four groups (P=0.001) (Figure 1F). Multivariate analysis showed significantly decreased overall mortality in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P=0.01) (Table 2). We also analyzed a subgroup of patients with standard risk (n=214) or high risk (n=221) at CBT. In standard-risk patients, the hazard risk of overall mortality (P=0.04), treatment failure (P=0.01) and relapse (P=0.002) was significantly lower in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group, while that of high-risk patients was not (*Online Supplementary Table S1 and Figures S1 and S2*).

Anti-leukemia effects of allo-HSCT consist of leukemia eradication by both a conditioning regimen of chemotherapy with or without radiation and the graft-versus-leukemia (GvL) effect. Since relapse is the most common cause of death after allo-HSCT, an intensified conditioning regimen or enhancement of GvL effects is needed to reduce the incidence of relapse. Because of the difficulty in controlling the degree of GvL effects, an intensified conditioning regimen has been extensively analyzed. The several improvements to a typical conditioning regimen have included the addition of other agents to a standard myeloablative regimen, a dose escalation of drugs or TBI, or administration of drugs other than CY. Among these, the addition of other agents to a standard myeloablative regimen has been the most commonly used.[5,6] In fact, several studies have reported a decrease in the incidence of relapse following intensified conditioning, but with a higher TRM, and no improvement in survival was achieved.[5,7] Furthermore, the effect of adding high-dose Ara-C to a TBI/CY myeloablative conditioning regimen is controversial.[7] However, all of these studies analyzed patients receiving BM or mobilized PB stem cell transplantation from related or unrelated donors. This finding was not confirmed in CBT. In our study, neutrophil and platelet engraftment was significantly higher in the TBI≥10Gy+Ara-C+CY group compared with the TBI≥10Gy+other group, suggesting that the addition of Ara-C to TBI/CY was beneficial in terms of stable engraftment, but not for survival in CBT for AML.

Granulocyte colony-stimulating factor was originally identified as an agent for stimulation of neutrophil production. Although G-CSF is most commonly used to reduce the duration of neutropenia after chemotherapy, it is also commonly used for hematopoietic stem cell (HSC) mobilization for HSCT. Although the mechanism of HSC mobilization is not clearly understood, G-CSF could disrupt the contact between HSC in a BM niche, leading to HSC migration. In a mouse bone marrow transplantation (BMT) model, G-CSF prior to low-dose irradiation enhanced donor HSC engraftment.[14] This effect might be mainly due to the migration of recipient HSC from a BM niche by G-CSF treatment before transplantation. In fact, our data showed that neutrophil engraftment was significantly higher in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group. These data suggest that the effect of the addition of G-CSF to a conditioning regimen could enhance neutrophil engraftment after CBT.

It has been reported that the administration of G-CSF increased the susceptibility of the cell-cycle-specific agent Ara-C in leukemia cells *in vitro* and in a xenograft model.[8,9,15] In clinical studies, several regimens have attempted to demonstrate the efficacy of concomitant use of G-CSF with chemotherapy for newly diagnosed AML.[10,11] We hypothesized that the addition of G-CSF to a conditioning regimen might improve outcome in an allo-HSCT setting. In our study, relapse was significantly lower in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group. In a subgroup analysis, the effect of a G-CSF combination regimen for reduced relapse was significant in standard-risk but not high-risk patients. This is similar to a previous prospective randomized study of concomitant use of G-CSF with chemotherapy by Löwenberg *et al.*[11] Further studies are required to confirm which subgroup of patients with AML could benefit from a G-CSF combination regimen in CBT to reduce the incidence of relapse.

In conclusion, our data show that the addition of G-CSF-combined Ara-C to a TBI+CY conditioning regimen resulted in a significantly higher incidence of neutrophil engraftment and significantly better DFS and OS, and a reduced relapse rate in CBT for AML. Although these findings should be confirmed in prospective studies, a G-CSF-combined myeloablative conditioning regimen promotes better engraftment and survival results in CBT for AML.

Takaaki Konuma,[1] Jun Ooi,[2] Naoyuki Uchida,[3] Hiroyasu Ogawa,[4] Kazuteru Ohashi,[5] Heiwa Kanamori,[6] Nobuyuki Aotsuka,[7] Yasushi Onishi,[8] Hiroki Yamaguchi,[9] Yasuji Kozai,[10] Tokiko Nagamura-Inoue,[11] Koji Kato,[12] Ritsuro Suzuki,[13] Yoshiko Atsuta,[14,15] Seiko Kato,[1] Shigetaka Asano,[16] and Satoshi Takahashi[17]

[1]Department of Hematology and Oncology, The Institute of Medical Science, The University of Tokyo; [2]Department of Hematology and Oncology, Teikyo University School of Medicine, Tokyo; [3]Department of Hematology, Toranomon Hospital, Tokyo; [4]Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya; [5]Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo; [6]Department of Hematology, Kanagawa Cancer Center, Yokohama; [7]Division of Hematology-Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan; [8]Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; [9]Department of Hematology, Nippon Medical School, Tokyo; [10]Department of Transfusion Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo; [11]Department of Cell Processing and Transfusion, Research Hospital, The Institute of Medical Science, The University of Tokyo; [12]Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital; [13]Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine; [14]Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya; [15]Nagoya University Graduate School of Medicine; [16]System Medical Biology Laboratory, School of Advanced Science and Engineering, Waseda University, Tokyo; and [17]Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan

Correspondence: tkonuma@ims.u-tokyo.ac.jp
doi:10.3324/haematol.2014.114504

Key words: cord blood transplantation, conditioning regimen, granu-

locyte colony-stimulating factor, acute myeloid leukemia

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

References

1. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004; 104(12):3813-20.
2. Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109(3):1322-30.
3. Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113(8):1631-8.
4. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653-60.
5. Kanda Y, Sakamaki H, Sao H, Okamoto S, Kodera Y, Tanosaki R, et al. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant. 2005;11(11):881-9.
6. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica. 2002;87(1):52-8.
7. Riddell S, Appelbaum FR, Buckner CD, Stewart P, Clift R, Sanders J, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol. 1988;6(4):576-82.
8. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood. 1989;73(5):1272-8.
9. Takahashi S, Okamoto SI, Shirafuji N, Ikebuchi K, Tani K, Shimane M, et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant. 1994;13(3):239-45.
10. Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood. 2012; 119(23):5367-73.
11. Löwenberg B, van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743-52.
12. Mori T, Tanaka M, Kobayashi T, Ohashi K, Fujisawa S, Yokota A, et al. Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2013;19(3):486-91.
13. Konuma T, Kato S, Ooi J, Oiwa-Monna M, Ebihara Y, Mochizuki S, et al. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission. Biol Blood Marrow Transplant. 2014; 20(3):396-401.
14. Mardiney M 3rd, Malech HL. Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood. 1996;87(10):4049-56.
15. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010; 28(3):275-80.

Experimental Hematology

Experimental Hematology 2015;43:79–88

Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model

Yusuke Nakauchi[a], Satoshi Yamazaki[a], Stephanie C. Napier[b], Jo-ichi Usui[c], Yasunori Ota[d], Satoshi Takahashi[e], Nobukazu Watanabe[b], and Hiromitsu Nakauchi[a,f]

[a]*Division of Stem Cell Therapy, Centre for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan;* [b]*Laboratory of Diagnostic Medicine, Division of Stem Cell Therapy, Centre for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan;* [c]*Department of Nephrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan;* [d]*Department of Pathology, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan;* [e]*Department of Hematology/Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan;* [f]*Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA*

(Received 24 August 2014; revised 15 October 2014; accepted 22 October 2014)

Graft-versus-host disease (GVHD), mediated by donor-derived alloreactive T cells, is a major cause of nonrelapse mortality in allogeneic hematopoietic stem cell transplantation. Its therapy is not well-defined. We established allele-specific anti-human leukocyte antigen (HLA) monoclonal antibodies (ASHmAbs) that specifically target HLA molecules, with steady death of target-expressing cells. One such ASHmAb, against HLA-A*02:01 (A2-kASHmAb), was examined in a xenogeneic GVHD mouse model. To induce fatal GVHD, non-irradiated NOD/Shi-scid/IL-2Rγ^{null} mice were injected with healthy donor human peripheral blood mononuclear cells, some expressing HLA-A*02:01, some not. Administration of A2-kASHmAb promoted the survival of mice injected with HLA-A*02:01-expressing peripheral blood mononuclear cells ($p < 0.0001$) and, in humanized NOD/Shi-scid/IL-2Rγ^{null} mice, immediately cleared HLA-A*02:01-expressing human blood cells from mouse peripheral blood. Human peripheral blood mononuclear cells were again detectable in mouse blood 2 to 4 weeks after A2-kASHmAb administration, suggesting that kASHmAb may be safely administered to GVHD patients without permanently ablating the graft. This approach, different from those in existing GVHD pharmacotherapy, may open a new door for treatment of GVHD in HLA-mismatched allogeneic hematopoietic stem cell transplantation. **Copyright © 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).**

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure hematologic disorders like leukemia [1]. Cord blood or haplo-identical-donor HSCT holds promise for patients without a human leukocyte antigen (HLA)-matched donor. However, HLA-mismatched allo-HSCT may be complicated by alloreactive T cell-mediated graft-versus-host disease (GVHD), a major cause of mortality (after recurrent original disease) in allo-HSCT [2]. Although moderate GVHD induces a graft-versus-tumor effect and reduces disease relapse [3–6], severe GVHD confers a poor prognosis, as it is difficult to control. Agents used to treat GVHD include steroids [7], calcineurin inhibitors [8], and anti-thymocyte globulin (ATG) [9,10]. While these work well, they have many side effects (opportunistic infection, anaphylaxis-like reactions, etc.), which clinicians must carefully monitor.

Antithymocyte globulin endures as an antibody-based drug for GVHD treatment; however, its polyclonality and nonspecified target molecule cause it to react not only with T cells but also with other cells [9,10]. Current alternative therapies include monoclonal antibodies such as anti-CD3 [11] and anti-CD52 [12,13]. These antibodies have target molecules far more specific than those of ATG, but they cannot discriminate host cells from donor cells, resulting in opportunistic infection and other serious adverse effects.

Offprint requests to: Satoshi Yamazaki, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639 Japan; E-mail: y-sato4@ims.u-tokyo.ac.jp

Supplementary data related to this article can be found online at http://dx.doi.org/10.1016/j.exphem.2014.10.008.

0301-472X/Copyright © 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
http://dx.doi.org/10.1016/j.exphem.2014.10.008

One major shortcoming of all current GVHD therapies is that they affect every cell without distinction between donor and recipient cells. Damage to cells of both the donor and the recipient causes side effects that impair long-term prognosis such as organ failure and immune compromise. Therefore, we suggest a novel therapeutic approach to GVHD using an antibody that specifically recognizes a donor HLA molecule and damages only donor-derived cells.

Flow cytometry using anti-HLA antibodies is useful for determination of chimerism and minimal residual disease after HLA-mismatched HSCT [14]. Allele-specific anti-HLA monoclonal antibodies (ASHmAbs) are notoriously more difficult to generate than are non-allele-specific anti-HLA antibodies. However, we established a rapid and efficient strategy to generate ASHmAb using HLA-transgenic mice [15]. Allele-specific antibodies thus generated can damage target cells quickly and selectively; we assessed whether or not ASHmAb can treat GVHD in a mouse model. This report describes the success of a novel therapeutic approach to GVHD with ASHmAb that recognizes donor and recipient cells allele-specifically, damaging only donor-derived cells.

Methods

Mice

NOD/Shi-Scid Jic (NOD/SCID) mice were purchased from Sankyo Laboratory (Ibaraki, Japan). NOD/Shi-scid/IL-2Rγ^{null} (NOG) mice were purchased from the Central Institute for Experimental Animals (Kanagawa, Japan). HLA-B51 (B*5101) transgenic mice were all bred and maintained in the Animal Research Facility of the Institute of Medical Science, University of Tokyo. Animal care in our laboratory was in accordance with the guidance of the University of Tokyo for animal and recombinant DNA experiments.

Human samples

Human peripheral blood mononuclear cells (PBMCs) were collected from healthy donors at the University of Tokyo, and human cord blood was obtained from the Japanese Red Cross Kanto-Koshinetsu Cord Blood Bank, according to protocols approved by the institutional review board of the Institute of Medical Science, University of Tokyo. Mononuclear cells were isolated by centrifugation of human PBMCs on Lymphosepar I (Immuno-Biological Laboratories, Gunma, Japan). The isolated cells were washed once with ice-cold phosphate-buffered saline, suspended in a small volume of phosphate-buffered saline containing 5% mouse serum (Dako, Glostrup, Denmark) to block nonspecific fluorescence-labeled antibody binding to immunoglobulin Fc receptors, and kept on ice until staining.

Flow cytometric analysis

Studies of human-derived cells in humanized mice or GVHD model mice were performed using fluorescein isothiocyanate-conjugated anti-HLA-A9 (OneLambda, Canoga Park, CA, USA) and anti-human lineage CD3, 14, 16, 19, 20, and 56 (BioLegend, San Diego, CA, USA); phycoerythrin (PE)-conjugated anti-HLA A2 (BD Biosciences, San Jose, CA) and anti-CD56 (BioLegend); PE/cyanine (Cy) 5-conjugated anti-CD235ab (BD Biosciences); peridinin chlorophyll/Cy5.5-conjugated anti-CD8 (BioLegend); PE/Cy7-conjugated anti-CD3, anti-CD33 (BD Biosciences) and anti-CD38 (BD Biosciences); allophycocyanin (APC)-conjugated anti-CD3 (BioLegend) and anti-CD34 (BD Biosciences); APC/Cy7-conjugated anti-CD19 (BioLegend); Pacific blue-conjugated anti-CD4 and anti-CD45 (BioLegend); and Alexa Fluor 405- or 647-conjugated anti-CD45 (BioLegend). Propidium iodide (PI, 1 μg/mL; Sigma–Aldrich, St. Louis, MO, USA) was added to samples to stain dead cells just before flow cytometric analysis. Becton-Dickinson AriaII & CantoII fluorescence-activated cell sorters were used for all multicolor FACS analysis and sorting. Flow cytometry standard data were analyzed using FlowJo software (Treestar, Ashland, OR, USA).

Establishment of ASHmAb

We followed the method of Yamazaki et al. to generate ASHmAb [15] using PE-conjugated anti-HLA A2 tetramer loaded with NLVPMVATV peptide (HLA-A*02:01-restricted human cytomegalovirus-specific epitope pp65) and PE-conjugated anti-HLA A24 tetramer loaded with QYDPVAALF peptide (HLA-A*24:02-restricted human cytomegalovirus-specific epitope pp65), which were purchased from Medical and Biological Laboratories (Nagoya, Japan). FlowPRA screening (OneLambda) was performed according to the manufacturer's instructions. The isotypes of kASHmAb selected were IgM (HLA-A9) and IgG2b (HLA-A2) by Rodent Monoclonal Isotyping Strips (AbD Serotec, Kidlington, UK). We used an Alexa Fluor 647 monoclonal antibody labeling kit (Life Technologies, Carlsbad, CA, USA) to label kASHmAbs.

Examinations of peripheral blood

Analyses of mouse retro-orbital venous plexus blood samples were performed using a Celltac α (Nihon Kohden, Tokyo, Japan) to obtain complete blood counts and a Dri-Chem 3000 (Fujifilm, Tokyo, Japan) to measure serum total bilirubin and lactate dehydrogenase, alanine aminotransferase, and aspartate aminotransferase activities.

Xenogeneic model of GVHD

Non-irradiated female NOG mice 9 to 10 weeks old were injected intravenously with 1.0×10^7 human PBMCs (day 0) and were treated with ASHmAb (3 μg/g/day) on days 3 and 4 (total dose: 120 μg/mouse).

Purification of human CD34-positive cells and xenogeneic transplantation

Human CD34-positive cells from cord blood mononuclear cells were enriched using anti-human CD34 Micro-beads (Miltenyi Biotec, Bergisch Gladbach, Germany). For transplantation, female NOD/SCID mice or NOG mice 6 to 8 weeks old were irradiated (1.5 to 2.0 Gy) before transplantation, and 1.0 to 2.0×10^5 live CD34-positive cells were injected by tail vein. Live cells were identified by microscopy as those able to exclude trypan blue.

Systemic assessment of GVHD

To evaluate GVHD symptoms, we chose objective measurements (loss of weight, change of body temperature, and changes in biomarker values). Body weights and body temperatures of all mice were determined twice weekly. The liver, gut, kidneys, and



Figure 1. Assessment of allele specificity of kASHmAbs. (**A**) To establish ASHmAb-producing clones, on day 28 hybridomas (Supplementary Fig. E1, online only, available at www.exphem.org) selected as producing anti-HLA antibody at initial screening were secondarily screened with FlowPRA, using flow cytometry (YNA2.8.2 and YNA2.12.2). Hybridoma culture supernatants were incubated with HLA-coated beads. After incubation, the beads were washed and stained with secondary antibodies. Bead fluorescence intensities were measured using a flow cytometer, and specificities of anti-HLA monoclonal antibodies were determined. Representative flow cytometry data are shown for a combination of FlowPRA beads coated with HLA-A*01:01, A*02:01, A*03:01, B*49:01, A*25:01, A*29:02, A*30:01, and control antigen or A*26:01. (**B**) Flow cytometric analysis of A2-ASHmAb with healthy donor PBMCs. PBMCs No. 2 express HLA-A*02:01; PBMCs No. 1 do not. We stained three types of PBMCs (PBMCs No. 1 only, PBMCs No. 2 only, and PBMCs No. 1 + No. 2) with Alexa Fluor 647-conjugated ASHmAb to assess this antibody's specificity. Cells from PBMCs No. 1 + No. 2 sorted as HLA-A2(+) were subjected to sequencing-based HLA typing. (**C**) Chimerism analysis of clinical samples using ASHmAb. In a 46-year-old man who underwent cord blood transplantation more than 12 years earlier for acute myeloid leukemia, we analyzed chimerism of whole PBMCs, B cells, T cells, natural killer cells, and monocytes using anti-HLA A2 (recipient), anti-HLA A24 (recipient and donor), and anti-human CD3, CD4, CD8, CD19, and CD56. Doublets and dead cells were excluded from flow cytometry data. ASHmAbs = allele-specific anti-human leukocyte antigen monoclonal antibodies; HLA = human leukocyte antigen; kASHmAbs = ASHmAbs; PBMCs = peripheral blood mononuclear cells.

lungs were collected from euthanized mice and analyzed by light microscopy of immunostained sections. Animal cages were maintained at room air temperature of 22°C to 23°C with a humidity of 55%.

Immunostaining of organ sections
Liver, lungs, guts, and kidneys from mice transplanted with human PBMCs were fixed with 10% buffered formalin and embedded in paraffin. Sections 5 μm thick were placed on glass slides (Matsunami Glass, Osaka, Japan), deparaffinized, incubated with anti-human CD3 and CD45 monoclonal antibodies (Dako) overnight at 4°C, and serially incubated with peroxidase-labeled polymer conjugated goat anti-mouse antibody (Nichirei, Tokyo, Japan) for 30 min at room temperature. These sections then were incubated with 0.02% 3,3-diaminobenzidine (Dojindo, Kumamoto, Japan) substrate solution containing 0.006% H_2O_2 and counterstained with hematoxylin for visualization of nuclei. TdT-mediated dUTP nick end labeling (TUNEL) staining (Medical and Biological Laboratories) was performed according to the manufacturer's instructions to permit evaluation of apoptosis.

Statistics
Mouse survival data are presented as Kaplan–Meier survival curves. Differences between groups were analyzed by log-rank testing with GraphPad Prism (GraphPad Software, San Diego, CA, USA). Differences between group means were tested using Student's t test, also with GraphPad Prism; values for which $p < 0.05$ were considered significant.

Results

Generation of ASHmAbs and their specificities
Using our established method [15], we developed a panel of ASHmAbs that recognize HLA alleles specifically. First, we immunized HLA class I transgenic mice with tetramers specific for HLA-A or HLA-B alleles [16]. After alloimmunity was confirmed by assay of sera from immunized mice, the mice were sacrificed and lymph node-derived cells and splenic cells were fused with SP2/0 myeloma cells to yield hybridoma cells (Supplementary Figure 1E, online only, available at www.exphem.org). We screened supernatants of hybridomas in single-clone culture by enzyme-linked immunosorbent assay to detect reactivity against the HLA tetramer (data not shown). Selected clones were expanded for panel-reactive antibody (PRA) screening, performed using FlowPRA (Fig. 1A). We chose several monoclonal antibodies for further work, one binding specifically to HLA-A*02:01 (YNA2.8.2) and one binding to both HLA-A*02:01 and HLA-A*03:01 (YNA2.12.2). We also established the antibodies that bind to HLA-A*23:01, HLA-A*24:02, and HLA-A*32:01 (Clone YNA24.3.2 and YNA24.19.2). Focusing on YNA2.8.2, we purified it and subjected it to biotinylation or to conjugation with the fluorescent chromophore AF647. Using this biotinylated ASHmAb or the ASHmAb's fluorescent conjugate, we analyzed

whether it could, in flow cytometry, distinguish members of two different HLA-positive healthy donor PBMC sets. We mixed PBMCs from two donors, one HLA-A2-positive and the other HLA-A2-negative, and stained the pool with biotinylated ASHmAb. Flow cytometry results revealed that we could distinctly separate the two types of cells (Fig. 1B). With sequencing-based typing (Special Reference Laboratories, Tokyo, Japan), we confirmed that cells sorted as HLA-A*02:01 positive were absolutely, by genetic criteria, HLA-A*02:01 expressing (data not shown). To confirm this antibody's specificity in vivo further, we analyzed PBMCs of a patient who underwent allo-HSCT to examine whether the antibody enabled separation of donor (HLA-A2-negative/A24-positive) cells from recipient (HLA-A2/A24-positive) cells (Fig. 1C). The patient was a 46-year-old man who 12 years earlier had undergone cord blood transplantation for acute myeloid leukemia and who suffered from chronic GVHD. Using YNA2.8.2, we could successfully separate the patient's PBMCs into donor- and recipient-derived cells. Chimerism analysis unexpectedly revealed that T cells, B cells, natural killer (NK) cells, and monocytes of native origin persisted in this patient after HSCT. These results confirm the reported utility of ASHmAbs as a diagnostic tool [14].

Allele-specific cytotoxicity of ASHmAb

To evaluate the killing ability of ASHmAb, we first analyzed in vitro cytotoxicity (Fig. 2A). HLA-A2-negative or -positive cells (1.0×10^6 cells/well) were cultured with ASHmAb hybridoma supernatant, Dulbecco's modified Eagle medium (Sigma–Aldrich), and 10% fetal bovine serum, with or without 30% baby rabbit complement, and were incubated for 24 hours (37°C, 5%CO_2). Percentages of dead cells were determined by PI staining of cells using a flow cytometer. On average, 61.9% of HLA-A2-positive cells were PI positive, and on average, only 14.2% of HLA-A2-negative cells were PI positive. These results indicate that ASHmAb can bind with HLA-A2-positive cells in vitro, a phenomenon resulting in cell death, presumably via complement-dependent cytotoxicity. We designated this ASHmAb that kills only HLA-A*02:01-positive cells as HLA-A2 killing ASHmAb (A2-kASHmAb). A2-kASHmAb was capable of killing target cells quickly: when we examined cell death after 3 hours of incubation, we found 30% to 40% mortality manifest as aggregation and failure of trypan blue exclusion (data not shown).

To analyze the cytotoxicity of A2-kASHmAb in vivo, we transplanted 1.0×10^5 cells/mouse cord blood-derived HLA-A2-negative or -positive mononuclear cells into CB17-Prkdc^{scid}/J (NOD/SCID) mice previously subjected to 2.0 Gy of irradiation and made human–mouse bone marrow chimeric mice (Fig. 2B). Before A2-kASHmAb injection (0.5 mg/mouse, intravenously), chimerism of cord blood-derived HLA-A2-positive cells was 12.0%; 1 day after injection, chimerism fell to 0.3%. Conversely, chimerism of cord blood-derived HLA-A2-negative cells before A2-kASHmAb injection was 2.3% and 1 day after injection, chimerism increased to 5.9% (Fig. 2C), an effect significantly different on statistical analysis (Fig. 2D, E). These experiments indicate that kASHmAb can damage cells allele-specifically in vitro and in vivo. We also found that kASHmAb administered intraperitoneally could damage target cells as efficiently as kASHmAb administered intravenously (Supplementary Figure E2A–C, online only, available at www.exphem.org).

Xenogeneic model of GVHD treatment with kASHmAb

We focused on kASHmAb's cytotoxicity and its ability to discriminate between donor and recipient cells. ATG, a representative clinical GVHD molecular-targeted agent, is used both as a treatment for and as a prophylactic against GVHD. However, ATG reacts against cells without distinguishing between donor and recipient cells and causes many side effects, such as allergic reaction and increased susceptibility to infection, as a result of repression of T cells. Moreover, the exact molecular target of ATG is unknown, because ATG is polyclonal. As kASHmAb induces donor-specific cell death in GVHD treatment and is directed against a clear molecular target, we thought that kASHmAb might be useful as a molecule-targeted drug in GVHD treatment as an alternative to ATG.

Ito et al. reported a novel xeno-GVHD animal model using NOG mice in which, thanks to intravenous transfer of human PBMCs, GVHD symptoms were of early onset [17]. We employed this model to analyze the therapeutic effect of kASHmAb in GVHD. We transplanted 1.0×10^7 cells/mouse HLA-A2-negative or -positive PBMCs into NOG mice without irradiation (day 0). To judge whether GVHD had developed or not, blood tests, determinations of body temperature and weight, and assays of skin damage were used in previous studies [18–20]. In this study, to ensure as objective a determination of the onset of GVHD as possible, we decided to define GVHD onset based on minor changes in biomarker values, body temperature, and body weight, as in clinical settings (Fig. 3C, Supplementary Figure E3, online only, available at www.exphem.org). Determinations of complete blood counts (CBC) and biomarkers in peripheral blood established that the onset of GVHD—as indicated by significant changes in complete blood count values—was 3 days after PBMC injection. We thus decided to start administration of A2-kASHmAb from this point with A2-kASHmAb injection (days 3 and 4; 60 μg/day × 2 days) coupled with analysis of PBMCs by flow cytometry (Fig. 3A); complete blood count and biomarker determinations; records of body weight, body temperature, and calculated survival rate; and histopathologic analysis. First, using flow cytometry, we analyzed the frequency of human-derived cells in peripheral blood of GVHD model mice before and after



Figure 2. Allele-specific cytotoxicity of ASHmAbs. (**A**) Statistical analysis of in vitro killing assay using A2-ASHmAb with and without baby rabbit complement (right and left, respectively). HLA-A2(−) cells (*red bar*) and HLA-A2(+) cells (*blue bar*) from healthy donors were each cultured with isotype control or A2-ASHmAb hybridoma supernatant. Percentages of dead cells were determined by propidium iodide staining and flow cytometry. Doublets and dead cells were excluded from flow cytometry data. NC = negative control; NS = not significant. Data shown as mean ± SD ($n = 4$, $p < 0.05$ by Student's t test). (**B**) Schedule of in vivo assay of killing ASHmAbs. Cord blood-derived CD34(+)/HLA-A2(−) or CD34(+)/HLA-A2(+) cells were transplanted into NOD/SCID mice with 2 Gy of irradiation to create respectively HLA-A2(−) and HLA-A2(+) human–mouse bone marrow chimeric mice. One month after transplantation, peripheral blood was analyzed by flow cytometry just before kASHmAb injection and on days 1 and 7 thereafter. (**C**) Representative flow cytometric analyses. Top: HLA-A2(−)/CD45(+) cells (%) among HLA-A2(−) mouse peripheral blood mononuclear cells in marked gate. Bottom: HLA-A2(+)/CD45(+) cells (%) among HLA-A2(+) mouse PBMCs in marked gate. Doublets and dead cells were excluded from flow cytometry data. (**D, E**) Statistical analysis of (**C**). *Red bars* and *blue bars* respectively represent HLA-A2(−) and HLA-A2(+) cells. Data shown as mean ± SD ($n = 3$ and 5, respectively; $p < 0.05$ by Student's t test). HLA = human leukocyte antigen; kASHmAbs = killing allele-specific anti-human leukocyte antigen monoclonal antibodies; NS = not significant; PBMCs = peripheral blood mononuclear cells.

A2-kASHmAb administration (Fig. 3B). Chimerism of the HLA-A2-positive group was 5.4% before A2-kASHmAb injection; on day 8 after PBMC injection, it was 0%. Chimerism of the HLA-A2-negative group was 8.8% immediately before A2-kASHmAb injection; on day 8 after PBMC injection, it was 27.8%. The survival rate of the HLA-A2-positive group was 100%, with a mean survival of more than 6 months; however, all members of the HLA-A2-negative group died within 2 months (Fig. 3D). To confirm that GVHD had caused death, we histopathologically examined liver, lungs, intestine, and kidneys of these mice. Immunostaining revealed intensive tissue infiltration by CD3-positive/CD45-positive cells, especially in lungs and intestine (Fig. 3E, Supplementary Figure E4, online only, available at www.exphem.org), and TdT-mediated dUTP nick end labeling studies revealed apoptosis (Supplementary Figure E5, online only, available at www.exphem.org). These results verified experimentally that kASHmAb could be a novel drug to damage target cells in GVHD safely, quickly, and selectively.



Figure 3. GVHD kASHmAb treatment model. (**A**) Schedule, GVHD kASHmAb treatment model. Day −1: Blood examination. Day 0: HLA-A2(−) or HLA-A2(+) PBMCs transplanted into non-irradiated NOG mice. Day 3: Blood examination immediately before first kASHmAb dose; first kASHmAb dose. Day 4: Second kASHmAb dose. Days 2, 8, and 28: Flow cytometric analyses. Day 90: Survival assessment. (**B**) Representative flow cytometric analyses. Human-derived cells (%) among GVHD model mouse PBMCs, days 3, 8, and 28. Top: HLA-A2(−)/CD45(+) cells, HLA-A2(−) GVHD mouse. Bottom: HLA-A2(+)/CD45(+) cells in HLA-A2(+) GVHD mouse. Forward-scatter, side-scatter, and propidium iodide gatings excluded residual erythrocytes, debris, doublets, and dead cells. (**C**) Body weight of GVHD model mice before and after kASHmAb treatment. *Red line* = HLA-A2(−) PBMC-transplanted mice = GVHD(+); *blue line*: HLA-A2(+) PBMC-transplanted mice = GVHD(−)]. Weight was determined twice weekly between 1500 and 1900 hours at room temperature (22°C) and ambient humidity (55%). Percentage change from initial weight is illustrated. (**D**) Survival of GVHD model mice (kASHmAb-treated). *Red* and *blue lines* respectively represent HLA-A2(−) GVHD mice and HLA-A2(+) GVHD mice. Data shown as Kaplan–Meier estimates (n = 4 and 5, respectively; $p < 0.05$).



Figure 3. (*continued*) (E) Lung and intestine, day 21, GVHD model mice (NOG mice intravenously transplanted with human PBMCs (HLA-A2(−) or HLA-A2(+)); anti-human CD3 and CD45 developed with 3,3′-diaminobenzidine, hematoxylin nuclear counterstaining. × 200. Bar = 400 μm. A = alveoli; Br = bronchiole; GVHD = graft-versus-host disease; HE = hematoxylin and eosin; HLA = human leukocyte antigen; kASHmAbs = allele-specific anti-HLA monoclonal antibodies against HLA-A*02:01; LP = lamina propria; Lu = lumen; M = muscularis; NOG = NOD/Shi-scid/IL-2Rγ^{null}; PBMCs = peripheral blood mononuclear cells; S = submucosa.

kASHmAb administration did not cause graft failure

We confirmed that A2-kASHmAb specifically damages cells that express HLA-A2 in human–mouse bone marrow chimera mice (Fig. 2C, D). A potential risk of anti-GVHD therapy with kASHmAb is damage to donor hematopoietic stem cells (HSCs) that necessitates another transplantation. Unexpectedly, we discovered that in many mice (14 of 16) in the HLA-A2-positive group chimerism rebounded to high levels 1 to 2 months after A2-kASHmAb injection. The dose of kASHmAb used to treat GVHD was, at greatest, equivalent to that of the polyclonal ATG preparation usually given for acute GVHD in actual clinical settings (3 mg/kg/day × 5 days). The clinical risk might be substantial if kASHmAbs were administered to GVHD patients, because if donor-derived HSCs are ablated, patients may have to undergo HSCT again. The observation that chimerism returns quickly after A2-kASHmAb administration let us hypothesize that HSCs resist antibody-mediated killing and that adjusting the dose of kASHmAb may circumvent damage to HSCs while yet treating GVHD.

We used humanized mice, generated by transplanting 2.0 × 10^5 cells/mouse cord blood-derived HLA-A2-positive/CD34-positive cells into NOG mice after 1.5 Gy irradiation, to track numbers of cord blood-derived HLA-A2-positive/CD45-positive human cells among mouse PBMCs and bone marrow cells after high-dose A2-kASHmAb (60 μg/day × 2 days) administration (Fig. 4A). PBMC human cell chimerism in humanized mice immediately before A2-kASHmAb injection was 72.2%; 2 days after A2-kASHmAb injection, it was 12.9%. Although most CD34-positive cord blood-derived cells disappeared after A2-kASHmAb injection, human cell high chimerism (70.7%) returned in the same mice within 1 month (Fig. 4B, C). We determined numbers of human cells in mouse PBMCs and bone marrow cells before and after A2-kASHmAb injection. Although many human PBMCs disappeared, the proportion of human-derived cells in bone marrow continued to be substantial (Fig. 4D). HLA resides on the surface of all nucleated cells, including HSCs [21,22]; these results unexpectedly indicated that the killing ability of kASHmAb is selective,



Fig. 4. Humanized mice: kASHmAb treatment without graft failure. (**A**) Schedule. (**B**) Representative flow cytometric analyses. Cord blood-derived human cells (%) among PBMCs of irradiated NOD/Shi-scid/IL-2Rγ^{null} (NOG) mice given HLA-A2(+)/CD34(+) cord blood cells; "humanized mice," day −1 (day before intraperitoneal kASHmAb injection) and days 2, 7, 28, 56, and 84. Abscissa: Human CD45; ordinate: HLA-A2. Forward-scatter, side-scatter, and propidium iodide gatings excluded residual erythrocytes, debris, doublets, and dead cells. (**C**) Bars: HLA-A2(+)/CD45(+) cells (%) among humanized mouse PBMCs. The data are normalized against the baseline percentage of human cells. Data shown as mean ± SD (n = 5). (**D**) Representative flow cytometric analyses of cord blood-derived human cells (%) among bone marrow cells, say 84. Mouse bone marrow cells were stained with anti-human CD34 and anti-human CD38 antibodies. Forward-scatter, side-scatter, and propidium iodide gatings excluded residual erythrocytes, debris, doublets, and dead cells. HLA = human leukocyte antigen; kASHmAbs = killing allele-specific anti-HLA monoclonal antibodies against HLA-A*02:01; NOG = NOD/Shi-scid/IL-2Rγ^{null}; PBMCs = peripheral blood mononuclear cells.

damaging cells in peripheral blood more efficiently than those in bone marrow. These findings indicated that at the correct dose, kASHmAb likely could be administered to GVHD patients safely, without causing graft failure and necessitating repeat HSCT.

Discussion

Emergence of antibodies to HLA antigens is often associated with disorders such as graft failure and resistance to transfusion [23–27]. This study is the first to find that anti-HLA antibodies also can be used therapeutically. Confronted with growing numbers of HLA-mismatched cord blood or haplo-identical HSCT, we thought about generating kASHmAbs that can recognize donor HLA molecules in an allele-specific manner and damage them while sparing host cells. Because they act specifically against donor cells, these kASHmAbs, in principle, should constitute novel anti-GVHD drugs with minimum side effects. Indeed, unlike ATG and anti-CD3 or anti-CD52 antibodies, ASHmAbs destroyed donor cells specifically and quickly and thus treated acute GVHD efficiently, as shown in our